Mark C. Enright
Corporate Officer/Principal bij Imperial College London
Profiel
Mark C.
Enright is a Professor at Imperial College London since 2007.
He previously worked as a Research Director at AmpliPhi Biosciences Corp.
and Biocontrol Ltd.
(United Kingdom).
He obtained a doctorate degree from the University of Aberdeen.
Actieve functies van Mark C. Enright
Bedrijven | Functie | Begin |
---|---|---|
Imperial College London | Corporate Officer/Principal | 31-10-2011 |
Eerdere bekende functies van Mark C. Enright
Bedrijven | Functie | Einde |
---|---|---|
Biocontrol Ltd. (United Kingdom)
Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Mark C. Enright
University of Aberdeen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Biocontrol Ltd. (United Kingdom)
Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Health Technology |